{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:49:33Z","timestamp":1768805373428,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institutes of Health (US), Adult Brain Tumor Consortium","award":["UM1 CA137443"],"award-info":[{"award-number":["UM1 CA137443"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11060-016-2357-9","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T07:37:58Z","timestamp":1485157078000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas"],"prefix":"10.1007","volume":"132","author":[{"given":"Lakshmi","family":"Nayak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Wefel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy T.","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred W. K.","family":"Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Prados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"2357_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1634\/theoncologist.2008-0272","volume":"14","author":"AS Chi","year":"2009","unstructured":"Chi AS, Sorensen AG, Jain RK, Batchelor TT (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14:621\u2013636. doi: 10.1634\/theoncologist.2008-0272","journal-title":"Oncologist"},{"key":"2357_CR2","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740. doi: 10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"key":"2357_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745. doi: 10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"key":"2357_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. doi: 10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"key":"2357_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709\u2013722. doi: 10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"key":"2357_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1517\/13543784.2014.856880","volume":"23","author":"I Arrillaga-Romany","year":"2014","unstructured":"Arrillaga-Romany I, Reardon DA, Wen PY (2014) Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs 23:199\u2013210. doi: 10.1517\/13543784.2014.856880","journal-title":"Expert Opin Investig Drugs"},{"key":"2357_CR7","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","volume":"29","author":"JF Groot de","year":"2011","unstructured":"de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY (2011) Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29:2689\u20132695. doi: 10.1200\/JCO.2010.34.1636","journal-title":"J Clin Oncol"},{"key":"2357_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2004.10.011","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553\u2013563. doi: 10.1016\/j.ccr.2004.10.011","journal-title":"Cancer Cell"},{"key":"2357_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.ijrobp.2006.11.011","volume":"67","author":"PR Wachsberger","year":"2007","unstructured":"Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP (2007) VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 67:1526\u20131537. doi: 10.1016\/j.ijrobp.2006.11.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2357_CR10","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085\u20134091. doi: 10.1200\/JCO.2013.49.6968","journal-title":"J Clin Oncol"},{"key":"2357_CR11","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1200\/JCO.2009.27.1932","volume":"28","author":"M Brada","year":"2010","unstructured":"Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601\u20134608. doi: 10.1200\/JCO.2009.27.1932","journal-title":"J Clin Oncol"},{"key":"2357_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","volume":"19","author":"TN Tombaugh","year":"2004","unstructured":"Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203\u2013214. doi: 10.1016\/S0887-6177(03)00039-8","journal-title":"Arch Clin Neuropsychol"},{"key":"2357_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/clin.12.1.43.1726","volume":"12","author":"RHB Benedict","year":"1998","unstructured":"Benedict RHB, Schretien D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43\u201355","journal-title":"Clin Neuropsychol"},{"key":"2357_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/arclin\/11.4.329","volume":"11","author":"RM Ruff","year":"1996","unstructured":"Ruff RM, Light RH, Parker SB, Levin HS (1996) Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol 11:329\u2013338","journal-title":"Arch Clin Neuropsychol"},{"key":"2357_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/1385404049052420","volume":"18","author":"AJ Levine","year":"2004","unstructured":"Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA (2004) Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol 18:373\u2013384. doi: 10.1080\/1385404049052420","journal-title":"Clin Neuropsychol"},{"key":"2357_CR16","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2013.49.6067","volume":"31","author":"TS Armstrong","year":"2013","unstructured":"Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M (2013) Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31:4076\u20134084. doi: 10.1200\/JCO.2013.49.6067","journal-title":"J Clin Oncol"},{"key":"2357_CR17","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(13)70308-5","volume":"14","author":"NU Lin","year":"2013","unstructured":"Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY, Response Assessment in Neuro-Oncology g (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 14: e407\u2013416 doi: 10.1016\/S1470-2045(13)70308-5","journal-title":"Lancet Oncol"},{"key":"2357_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","volume":"12","author":"MJ Bent van den","year":"2011","unstructured":"van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583\u2013593. doi: 10.1016\/S1470-2045(11)70057-2","journal-title":"Lancet Oncol"},{"key":"2357_CR19","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1158\/1078-0432.CCR-11-0271","volume":"17","author":"JF Groot de","year":"2011","unstructured":"de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV (2011) Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 17:4872\u20134881. doi: 10.1158\/1078-0432.CCR-11-0271","journal-title":"Clin Cancer Res"},{"key":"2357_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/neuonc\/nov019","volume":"17","author":"U Lassen","year":"2015","unstructured":"Lassen U, Chinot OL, McBain C, Mau-Sorensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M (2015) Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-oncology 17:1007\u20131015. doi: 10.1093\/neuonc\/nov019","journal-title":"Neuro-oncology"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-016-2357-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:50:15Z","timestamp":1498380615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-016-2357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1007\/s11060-016-2357-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}